AAAlireza Abadi

Alireza Abadi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Alireza Abadi has a total of 20 co-authors. Here are the top co-authors by number of shared publications:

  • Bahar Mansoori

    Department of Radiology, Division of Abdominal Imaging, University of Washington, Seattle, WA 98105, USA

    2 shared publications
  • Majid Chalian

    Department of Radiology, Division of Musculoskeletal Imaging and Intervention, University of Washington, UW Radiology-Roosevelt Clinic, Seattle, USA

    2 shared publications
  • Alekhya Yechoor

    From the Department of Radiology, Divisions of Musculoskeletal Imaging and Intervention (H.C., A.Y., A.B.A., M. Shafiei, M.C.) and Nuclear Medicine (F.B.), University of Washington, UW Radiology-Roosevelt Clinic, 4245 Roosevelt Way NE, Box 354755, Seattle, WA 98105; Department of Radiology, Division of Musculoskeletal Imaging, NYU Langone Health, New York, NY (I.K.); and Department of Radiology, Division of Musculoskeletal Imaging, University of Utah, Salt Lake City, Utah (M. Soltanolkotabi)

    1 shared publication
  • Atefe Pooyan

    1 shared publication
  • Brian Mau

    1 shared publication
  • Charles Rohrmann

    From the Division of Abdominal Imaging, Department of Radiology, University of Washington, 1959 NE Pacific St, Seattle, WA 98195-7115 (S.M., A.A., C.R., P.B. B.M.); Division of Abdominal Imaging, Department of Radiology, Mayo Clinic, Jacksonville, Fla (D.D.); and Division of Abdominal Imaging, Department of Radiology, New York University, New York, NY (J.R.).

    1 shared publication

Latest Publications

  • Small Bowel Follow-Through in the Age of Cross-sectional Imaging

    by Shamus Moran, Alireza Abadi, David DiSantis, Jonathan Revels, Charles Rohrmann, Puneet Bhargava, Bahar Mansoori


  • Fibroblastic and Myofibroblastic Soft-Tissue Tumors: Imaging Spectrum and Radiologic-Pathologic Correlation

    by Sara Haseli, Bahar Mansoori, Diana Christensen, Alireza Abadi, Atefe Pooyan, Firoozeh Shomal Zadeh, Brian Mau, Nastaran Khalili, Mark Murphey, Majid Chalian

    Fibroblastic and myofibroblastic tumors are a variable group of neoplasms ranging from benign to malignant. These lesions may affect patients of any age group but are more frequently encountered in the pediatric population. Patient clinical presentation depends on the location, growth pattern, adjacent soft-tissue involvement, and pathologic behavior of these neoplasms. In the 2020 update to the World Health Organization (WHO) classification system, these tumors are classified on the basis of their distinct biologic behavior, histomorphologic characteristics, and molecular profiles into four tumor categories: (a) benign (eg, fibrous hamartoma of infancy, nodular fasciitis, proliferative fasciitis, fibroma of the tendon sheath, calcifying aponeurotic fibroma); (b) intermediate, locally aggressive (eg, desmoid fibromatosis); (c) intermediate, rarely metastasizing (eg, dermatofibrosarcoma protuberans, myxoinflammatory fibroblastic sarcoma, low-grade myofibroblastic sarcoma, infantile fibrosarcoma); and (d) malignant (eg, sclerosing epithelioid fibrosarcomas; low-grade fibromyxoid sarcoma; myxofibrosarcoma; fibrosarcoma, not otherwise specified). Detection of various components of solid tumors at imaging can help in prediction of the presence of corresponding histopathologic variations, thus influencing diagnosis, prognosis, and treatment planning. For example, lesions with a greater myxoid matrix or necrotic components tend to show higher signal intensity on T2-weighted MR images, whereas lesions with hypercellularity and dense internal collagen content display low signal intensity. In addition, understanding the radiologic-pathologic correlation of soft-tissue tumors can help to increase the accuracy of percutaneous biopsy and allow unnecessary interventions to be avoided. ©RSNA, 2023 Quiz questions for this article are available in the supplemental material.


  • Common Skeletal Neoplasms and Nonneoplastic Lesions at 18F-FDG PET/CT

    by Hoiwan Cheung, Alekhya Yechoor, Fatemeh Behnia, Alireza Behrad Abadi, Iman Khodarahmi, Maryam Soltanolkotabi, Mehrzad Shafiei, Majid Chalian

    Although it is challenging to differentiate benign from malignant bone lesions on the basis of standardized uptake values, fluorine-18 fluorodeoxyglucose PET/CT contributes significantly to the dia... Numerous primary and metastatic osseous lesions and incidental osseous findings are encountered at fluorine 18 (18F) fluorodeoxyglucose (FDG) PET/CT. These lesions show varying degrees of FDG uptak...